Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 with Bicalutamide and LH-RH Agonists in NCMPC
NCT02487823Phase 1Terminated
- Sponsor
- Institut Paoli-Calmettes
- Start
- Oct 2014
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of buparlisib in prostate cancer (PCa), sponsored by Institut Paoli-Calmettes. Primary endpoint: Maximum Tolerated Dose. Started Oct 2014; status: terminated.
02
Drugs
buparlisib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02487823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02487823.